130 related articles for article (PubMed ID: 11243402)
21. Modulation of the cellular pharmacology and clinical toxicity of 1-beta-D-arabinofuranosylcytosine.
Howell SB; Streifel JA; Pfeifle CE
Med Pediatr Oncol; 1982; 10 Suppl 1():81-91. PubMed ID: 6761570
[TBL] [Abstract][Full Text] [Related]
22. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
[TBL] [Abstract][Full Text] [Related]
24. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
[TBL] [Abstract][Full Text] [Related]
25. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
[TBL] [Abstract][Full Text] [Related]
26. Metabolism and toxicity of electroporated 1-beta-D-arabinofuranosylcytosine triphosphate in a human leukemia cell line.
Kubota M; Yorifuji T; Hashimoto H; Shimizu T; Mikawa H
Jpn J Cancer Res; 1990 Dec; 81(12):1314-9. PubMed ID: 2126001
[TBL] [Abstract][Full Text] [Related]
27. Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.
Momparler RL; Onetto-Pothier N; Bouffard DY; Momparler LF
Cancer Chemother Pharmacol; 1990; 27(2):141-6. PubMed ID: 2249330
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
29. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
30. In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Boise L; Westin E; Howe C; Pettit GR; Turner A; McCrady C
Biochem Pharmacol; 1991 Jul; 42(4):853-67. PubMed ID: 1867641
[TBL] [Abstract][Full Text] [Related]
31. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
32. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity.
Rauscher F; Cadman E
Cancer Res; 1983 Jun; 43(6):2688-93. PubMed ID: 6189585
[TBL] [Abstract][Full Text] [Related]
33. Interaction of arabinosyl nucleotides in K562 human leukemia cells.
Gandhi V; Plunkett W
Biochem Pharmacol; 1989 Oct; 38(20):3551-8. PubMed ID: 2479383
[TBL] [Abstract][Full Text] [Related]
34. Efficient formation of cytosine arabinoside-5'-triphosphate in leukemic blasts of human T-cell acute lymphoblastic leukemia.
Tanaka M; Yoshida S
Leuk Res; 1989; 13(10):931-6. PubMed ID: 2586146
[TBL] [Abstract][Full Text] [Related]
35. Formation of cytosine arabinoside-5'-triphosphate in different cultured lymphoblastic leukaemic cells with reference to their drug sensitivity.
Köhl U; Schwabe D; Montag E; Bauer S; Mieth B; Cinatl J; Cinatl J; Rohrbach E; Mainke M; Weissflog A
Eur J Cancer; 1995; 31A(2):209-14. PubMed ID: 7718327
[TBL] [Abstract][Full Text] [Related]
36. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
Braess J; Wegendt C; Jahns-Streubel G; Kern W; Keye S; Unterhalt M; Schleyer E; Hiddemann W
Br J Haematol; 2000 May; 109(2):388-95. PubMed ID: 10848830
[TBL] [Abstract][Full Text] [Related]
37. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Bhalla K; McCrady C
Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
[TBL] [Abstract][Full Text] [Related]
38. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Plunkett W; Nowak B; Keating MJ
Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
[TBL] [Abstract][Full Text] [Related]
39. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow.
Tanaka M
Leuk Res; 1993 Jul; 17(7):585-92. PubMed ID: 8326741
[TBL] [Abstract][Full Text] [Related]
40. Ara-CTP metabolism following hydroxyurea or methotrexate treatment in human leukemia cell lines.
Kubota M; Takimoto T; Kitoh T; Tanizawa A; Akiyama Y; Kiriyama Y; Mikawa H
Adv Exp Med Biol; 1989; 253B():363-7. PubMed ID: 2610124
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
